Clinical trials: CDK4/6 Inhibitor
Healthy Volunteers
Safety, Pharmacokinetic and Pharmacodynamic Study of the CDK 4/6 Inhibitor G1T28-1
This first-in-human (FIH) study will provide the first safety, PK, and PD data of G1T28-1 in humans and will allow further development of G1T28 1 in patients with cancer to reduce chemotherapy-induced myelosuppression.
- Trial name
- NCT02243150
- Testing
- G1T28-1 (CDK 4/6 Inhibitor)
- Where
- Netherlands
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- G1 Therapeutics, Inc.
Head and Neck Squamous Cell Carcinoma
Neoadjuvant Adebrelimab Plus Dalpiciclib in Head and Neck Squamous Cell Carcinoma
This study is a single arm phase II trial including 30 patients with III-IVB (according to the 8th edition of UICC/AJCC staging) locally advanced head and neck squamous cell carcinoma (HNSCC) eligible for resection, who receive…
- Trial name
- NCT06199271
- Testing
- Adebrelimab and dalpiciclib
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Zhongzheng Xiang